Literature DB >> 19743494

Hemodynamics, diuretics, and nesiritide: a retrospective VMAC analysis.

James B Young1, Mei Cheng, Roger M Mills.   

Abstract

HYPOTHESIS: Hypotension has been proposed as the cause of nesiritide-associated increases in serum creatinine (SCr); however, this hypothesis has not been tested.
METHODS: This retrospective evaluation of patients who had a pulmonary artery catheter and received nesiritide in the Vasodilation in the Management of Acute Congestive Heart Failure (VMAC) trial assessed hypotension, SCr elevation, concomitant therapy, and mortality. Patients were categorized by baseline pulmonary capillary wedge pressure (PCWP) and analyzed both for overall population and by diuretic dose.
RESULTS: Compared with patients with PCWP > 23 mm Hg (n = 105), patients with PCWP < or = 23 mm Hg (n = 49) had more hypotension within 24 hours of initiating nesiritide (16% vs 7%), but neither more SCr elevation by nominal day 30 (29% vs 28%) nor higher mortality (30 days: 8.2% vs 7.7%; 6 months: 29.0% vs 29.3%). The risk of hypotension was directly related to high dose diuretics (25% vs 6%; relative risk [RR]: 4.2; 95% confidence interval [CI]: 1.10-15.82) and was not significantly increased in patients without this concomitant treatment (10% vs 7%; RR: 1.4; 95% CI: 0.34-5.93). Additionally, high dose diuretics significantly increased the risk of SCr elevation (RR: 2.6; 95% CI: 1.03-6.64) and 6 month mortality (hazard ratio: 3.6; 95% CI: 1.19-10.63) in patients with PCWP < or = 23 mm Hg.
CONCLUSIONS: Hypotension is not the primary etiology for nesiritide-associated increases in SCr. High dose diuretics increase the risk of adverse outcomes in patients with PCWP < or = 23 mm Hg and should be reserved for patients in whom PCWPs are known to be markedly elevated. Copyright 2009 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19743494      PMCID: PMC6653749          DOI: 10.1002/clc.20620

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  23 in total

1.  BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy.

Authors:  Stephen S Gottlieb; D Craig Brater; Ignatius Thomas; Edward Havranek; Robert Bourge; Steven Goldman; Farere Dyer; Miguel Gomez; Donald Bennett; Barry Ticho; Evan Beckman; William T Abraham
Journal:  Circulation       Date:  2002-03-19       Impact factor: 29.690

2.  Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial.

Authors: 
Journal:  JAMA       Date:  2002-03-27       Impact factor: 56.272

3.  Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)

Authors:  E L Knight; R J Glynn; K M McIntyre; H Mogun; J Avorn
Journal:  Am Heart J       Date:  1999-11       Impact factor: 4.749

4.  Correlates and impact on outcomes of worsening renal function in patients > or =65 years of age with heart failure.

Authors:  H M Krumholz; Y T Chen; V Vaccarino; Y Wang; M J Radford; W D Bradford; R I Horwitz
Journal:  Am J Cardiol       Date:  2000-05-01       Impact factor: 2.778

5.  Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?

Authors:  G L Bakris; M R Weir
Journal:  Arch Intern Med       Date:  2000-03-13

6.  Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure.

Authors:  Junnichi Ishii; Masanori Nomura; Yuu Nakamura; Hiroyuki Naruse; Yoshihisa Mori; Takashi Ishikawa; Toshikazu Ando; Hiroshi Kurokawa; Takeshi Kondo; Youichi Nagamura; Kouji Ezaki; Hitoshi Hishida
Journal:  Am J Cardiol       Date:  2002-03-15       Impact factor: 2.778

7.  Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure?

Authors:  Grace L Smith; Viola Vaccarino; Mikhail Kosiborod; Judith H Lichtman; Susan Cheng; Suzanne G Watnick; Harlan M Krumholz
Journal:  J Card Fail       Date:  2003-02       Impact factor: 5.712

8.  The prognostic importance of different definitions of worsening renal function in congestive heart failure.

Authors:  Stephen S Gottlieb; William Abraham; Javed Butler; Daniel E Forman; Evan Loh; Barry M Massie; Christopher M O'connor; Michael W Rich; Lynne Warner Stevenson; James Young; Harlan M Krumholz
Journal:  J Card Fail       Date:  2002-06       Impact factor: 5.712

9.  Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD).

Authors:  Michael Domanski; James Norman; Bertram Pitt; Mark Haigney; Stephen Hanlon; Eliot Peyster
Journal:  J Am Coll Cardiol       Date:  2003-08-20       Impact factor: 24.094

10.  Diuretic resistance predicts mortality in patients with advanced heart failure.

Authors:  Gerald W Neuberg; Alan B Miller; Chris M O'Connor; Robert N Belkin; Peter E Carson; Anne B Cropp; David J Frid; Regina G Nye; Milton L Pressler; John H Wertheimer; Milton Packer
Journal:  Am Heart J       Date:  2002-07       Impact factor: 4.749

View more
  2 in total

1.  Effects of recombinant human brain natriuretic peptide on renal function in patients with acute heart failure following myocardial infarction.

Authors:  Yanbo Wang; Xinshun Gu; Weize Fan; Yanming Fan; Wei Li; Xianghua Fu
Journal:  Am J Transl Res       Date:  2016-01-15       Impact factor: 4.060

Review 2.  Effect of recombinant human brain natriuretic peptide (rhBNP) versus nitroglycerin in patients with heart failure: A systematic review and meta-analysis.

Authors:  Sijie Zhang; Zhiqian Wang
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.